Mark Baum, founder and CEO of Imprimis Pharmaceuticals.

The future of healthcare remains uncertain – what are the potential outcomes for ophthalmology?

What does analysis of the last five years of dry AMD literature tell us about the field?

Bone marrow stem cells for the treatment of retinal disease are closer than you might think.

Mid-stromal lamellar keratoplasty (MSLK) is a new surgical technique for advanced keratoconus.

Eyedrops for presbyopia.

ILM peeling for macular holes - not always necessary or without risk.

Using an audio interpretive tool to create artwork by, and for, the visually impaired.

Mounting evidence suggests intravitreal injections increase risk of PCR during cataract surgery – why?

Could a small biomimetic peptide be a promising alternative to anti-VEGF treatment?